Trial Profile
Adjunctive Lisdexamfetamine in Bipolar Depression
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2014
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Bipolar I disorders; Bipolar II disorders; Depression
- Focus Therapeutic Use
- Acronyms Adjunctive-LDX-in-BP
- 04 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 29 Oct 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.